MSR1 and COVID-19: COVID-19 patients showed the opposite trend, having an increase in the more immunomodulatory M2-like classical monocytes, defined as CD14high CD16− CD163high CD204+ CD206+, with a reduction in the M1-like phenotype (Figure 1B and Figure 2B).